Main Background

TriPReP® Tubex® BMC – Autologous Cell
Concentration System

TriPReP® Tubex® BMC – Autologous Cell
Concentration System

TriPReP® Tubex® BMC – Autologous Cell
Concentration System

TriPReP® Tubex® BMC is a closed, sterile, single-use autologous bone marrow cell concentrate system engineered for high cell yield, anti-inflammatory markers and reproducible regenerative results — at a more affordable cost for patient’s soft tissue degenerative conditions

TriPReP® Tubex® BMC is a closed, sterile, single-use autologous bone marrow cell concentrate system engineered for high cell yield, anti-inflammatory markers and reproducible regenerative results — at a more affordable cost for patient’s soft tissue degenerative conditions

TriPReP® Tubex® BMC is a closed, sterile, single-use autologous bone marrow cell concentrate system engineered for high cell yield, anti-inflammatory markers and reproducible regenerative results — at a more affordable cost for patient’s soft tissue degenerative conditions

Download brochure
Download brochure
Download brochure

Precision Concentration for Regeneration

TriPReP® Tubex® BMC is an autologous cell concentration system that isolates and concentrates regenerative fractions from the bone marrow and a cocktail of mononuclear cells, platelets ,anti-inflammatory and growth factors in just 15–20 minutes.

TriPReP® Tubex® BMC is an autologous cell concentration system that isolates and concentrates regenerative fractions from the bone marrow and a cocktail of mononuclear cells, platelets ,anti-inflammatory and growth factors in just 15–20 minutes.

Precision Concentration for Regeneration

TriPReP® Tubex® BMC is an autologous cell concentration system that isolates and concentrates regenerative fractions from the bone marrow and a cocktail of mononuclear cells, platelets ,anti-inflammatory and growth factors in just 15–20 minutes.

Core Differentiator: We Deliver the Dose That Matters

Microcell Strainer Technology: Built-in strainer eliminates bone particles and debris, ensuring pure BMC fractions.

High Stem Cell Recovery: >90% total nucleated cell recovery, >80% MSC viability.

Dual Volume Options: 25 mL or 50 mL input.

No Density Gradient Media: Avoids Ficoll or manual pipetting, maintaining natural cell integrity.

Core Differentiator: We Deliver the Dose That Matters

Microcell Strainer Technology: Built-in strainer eliminates bone particles and debris, ensuring pure BMC fractions.

High Stem Cell Recovery: >90% total nucleated cell recovery, >80% MSC viability.

Dual Volume Options: 25 mL or 50 mL input.

No Density Gradient Media: Avoids Ficoll or manual pipetting, maintaining natural cell integrity.

Available in two Variants for multispecialty use

Available in two Variants for multispecialty use
Visual
Tubex® BMC-S (Small):

25 mL bone marrow kit yields 4 mL cell concentrate

Visual
Tubex ® BMC-L (Large):

50 mL bone marrow yields 8–10 mL concentrate

Visual
Tubex® BMC-S (Small):

25 mL bone marrow kit yields 4 mL cell concentrate

Visual
Tubex ® BMC-L (Large):

50 mL bone marrow yields 8–10 mL concentrate

Core Differentiator: We Deliver the Dose That Matters

Microcell Strainer Technology: Built-in strainer eliminates bone particles and debris, ensuring pure BMC fractions.

High Cell Recovery: >90% total nucleated cell recovery

Dual Volume Options: 25 mL or 50 mL input.

No Density Gradient Media: Avoids Ficoll or manual pipetting, maintaining natural cell integrity.

Core Differentiator: We Deliver the Dose That Matters

Microcell Strainer Technology: Built-in strainer eliminates bone particles and debris, ensuring pure BMC fractions.

High Cell Recovery: >90% total nucleated cell recovery

Dual Volume Options: 25 mL or 50 mL input.

No Density Gradient Media: Avoids Ficoll or manual pipetting, maintaining natural cell integrity.

Clinical Evidence – “Backed by Regenerative Science”

Clinical Evidence – “Backed by Regenerative Science”

Avascular Necrosis: Hernigou et al., JBJS (2018) reported 70–90% success rates with concentrated bone marrow therapy, showing improved angiogenesis and bone remodeling.

Avascular Necrosis: Hernigou et al., JBJS (2018) reported 70–90% success rates with concentrated bone marrow therapy, showing improved angiogenesis and bone remodeling.

Non-Union Fractures: Pierce et al., Injury (2019) demonstrated that BMAC therapy reduced non-union incidence from 30% to <10%.

Non-Union Fractures: Pierce et al., Injury (2019) demonstrated that BMAC therapy reduced non-union incidence from 30% to <10%.

Osteochondral Defects: Giannini et al., AJSM (2020) showed that BMAC combined with scaffolds enhances cartilage and bone integration.

Osteochondral Defects: Giannini et al., AJSM (2020) showed that BMAC combined with scaffolds enhances cartilage and bone integration.

MSC Mechanism: BMAC delivers MSCs, progenitors, and bioactive molecules (VEGF, PDGF, BMP-2, IGF-1) — promoting osteogenesis, chondrogenesis, and angiogenesis

MSC Mechanism: BMAC delivers MSCs, progenitors, and bioactive molecules (VEGF, PDGF, BMP-2, IGF-1) — promoting osteogenesis, chondrogenesis, and angiogenesis

Performance Metrics – “Precision You Can Quantify”

Performance Metrics – “Precision You Can Quantify”
Feature / Benefit

TriPReP® Tubex® BMC

Conventional BMAC kits

Cell Recovery

The total amount of cloud storage space allocated for your files.

>90% TNC and MNC Viability

50–70%, variable viability

Mononuclear Cell Concentration

The speed at which you can upload and download files to and from the cloud.

5–7× baseline

2–4× baseline

Cell Concentration

The speed at which you can upload and download files to and from the cloud.

5–7× baseline

2–4× baseline

Nucleated Cell Recovery

The largest file size you can upload in a single action.

>90%

60–75%

System Type

The total amount of cloud storage space allocated for your files.

Closed, sterile, ISO 13485 certified

Open / semi-closed

Bone Debris Removal

The speed at which you can upload and download files to and from the cloud.

Microcell strainer present

Absent

Contamination Risk

The largest file size you can upload in a single action.

0% risk

Unclear

Volume Flexibility

Manage access with a specified number of user accounts per plan.

25 mL / 50 mL adjustable volumes

Fixed volume

Affordability

Manage access with a specified number of user accounts per plan.

Economical

Expensive

Potential Indications

  • Avascular Necrosis (AVN)
  • Non-Union Fractures
  • Osteochondral Defects (OCD)
  • Cartilage Repair / OA Adjunct
  • Spinal Fusion / Bone Defect Filling
Potential Indications
  • Avascular Necrosis (AVN)
  • Non-Union Fractures
  • Osteochondral Defects (OCD)
  • Cartilage Repair / OA Adjunct
  • Spinal Fusion / Bone Defect Filling

Answers to Common Questions

Answers to Common Questions

We’ve gathered the most frequently asked questions to help you better understand our AI services, pricing, and integration process.

We’ve gathered the most frequently asked questions to help you better understand our AI services, pricing, and integration process.

Support Avatar

Need more help?

We're here to answer any questions you may have.

Ask a Question

Support Avatar

Need more help?

We're here to answer any questions you may have.

Ask a Question

What is BMC and how is it different from PRP?

What makes TriPReP® Tubex® BMC unique?

What are the output volumes?

Can BMC be used with PRP or scaffolds?

Is it regulatory compliant?

What outcomes are seen in osteochondral defect (OCD) or cartilage lesions with BMC?

How effective is BMC therapy in treating non-union or delayed-union fractures?

When can functional recovery typically be observed after BMC therapy?

Can TriPReP® Tubex® BMC be combined with other biologics?

What makes TriPReP® Tubex® BMC more reliable than imported systems?

What is BMC and how is it different from PRP?

What makes TriPReP® Tubex® BMC unique?

What are the output volumes?

Can BMC be used with PRP or scaffolds?

Is it regulatory compliant?

What outcomes are seen in osteochondral defect (OCD) or cartilage lesions with BMC?

How effective is BMC therapy in treating non-union or delayed-union fractures?

When can functional recovery typically be observed after BMC therapy?

Can TriPReP® Tubex® BMC be combined with other biologics?

What makes TriPReP® Tubex® BMC more reliable than imported systems?

References

1. Hernigou P. et al. Journal of Bone and Joint Surgery (JBJS), 2018. “Bone marrow concentrate in avascular necrosis: angiogenic and osteogenic restoration.”

2. Pierce J.L. et al. Injury, 2019. “BMAC reduces non-union fracture rates.”

3. Giannini S. et al. American Journal of Sports Medicine (AJSM), 2020. “Osteochondral defect repair with bone marrow-derived cells and scaffold.”

4. Muschler G.F. et al. Clin Orthop Relat Res, 2017. “Autologous bone marrow as a cellular source for skeletal repair.”

Bring the Future of Regenerative Medicine to Your Patients — Today.

Request

a Demo

Get Started

Cta Image
Cta Image

Bring the Future of Regenerative Medicine to Your Patients — Today.

Request

a Demo

Get Started

Cta Image
Cta Image

Bring the Future of Regenerative Medicine to Your Patients — Today.

Request

a Demo

Get Started

Explore products